The Treatment of Chronic Hepatitis B: Focus on Adefovir-like Antivirals

Overview

Journal Ther Clin Risk Manag

Publisher Dove Medical Press

Date 2009 Feb 12

PMID 19209262

Citations 3

Authors

Hans Ludger Tillmann

Affiliations

Soon will be listed here.

Abstract

SEVERAL OPTIONS FOR THE TREATMENT OF HEPATITIS B HAVE BEEN LICENSED IN THE LAST YEARS: interferon, pegylated interferon, lamivudine, adefovir, entecavir, and telbivudine. In addition tenofovir has been licensed in the EU and is expected to be licensed in the USA in 2008. The antivirals can be divided into "lamivudine-like" and "adefovir-like", which clinically differ in their capacity to induce "YMDD" mutants, which are the hallmark of lamivudine resistance. The differing resistance profile makes them good combination partners, even in the absence of synergy in antiviral potency.

Citing Articles

Moving Fast Toward Hepatitis B Virus Elimination.

Bassit L, Ono S, Schinazi R Adv Exp Med Biol. 2021; 1322:115-138.

PMID: 34258739 PMC: 8988908. DOI: 10.1007/978-981-16-0267-2_5.

Preemptive adefovir versus lamivudine for prevention of hepatitis B reactivation in chronic hepatitis B patients undergoing chemotherapy.

Ho E, Yau T, Rousseau F, Heathcote E, Lau G Hepatol Int. 2015; 9(2):224-30.

PMID: 25788197 DOI: 10.1007/s12072-015-9612-6.

Regio- and enantioselective N-allylations of imidazole, benzimidazole, and purine heterocycles catalyzed by single-component metallacyclic iridium complexes.

Stanley L, Hartwig J J Am Chem Soc. 2009; 131(25):8971-83.

PMID: 19480431 PMC: 2841989. DOI: 10.1021/ja902243s.

References

You J, Zhuang L, Cheng H, Yan S, Yu L, Huang J . Efficacy of thymosin alpha-1 and interferon alpha in treatment of chronic viral hepatitis B: a randomized controlled study. World J Gastroenterol. 2006; 12(41):6715-21. PMC: 4125683. DOI: 10.3748/wjg.v12.i41.6715. View

Cornberg M, Protzer U, Dollinger M, Petersen J, Wedemeyer H, Berg T . [Prophylaxis, Diagnosis and Therapy of Hepatitis-B-Virus-(HBV-)Infection: upgrade of the guideline, AWMF-Register 021/011]. Z Gastroenterol. 2007; 45(6):525-74. DOI: 10.1055/s-2007-963232. View

Dienstag J, Schiff E, Wright T, Perrillo R, Hann H, Goodman Z . Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med. 1999; 341(17):1256-63. DOI: 10.1056/NEJM199910213411702. View

Hezode C, Chevaliez S, Bouvier-Alias M, Roudot-Thoraval F, Brillet R, Zafrani E . Efficacy and safety of adefovir dipivoxil 20 mg daily in HBeAg-positive patients with lamivudine-resistant hepatitis B virus and a suboptimal virological response to adefovir dipivoxil 10 mg daily. J Hepatol. 2007; 46(5):791-6. DOI: 10.1016/j.jhep.2007.01.018. View

Jacquard A, Brunelle M, Pichoud C, Durantel D, Carrouee-Durantel S, Trepo C . In vitro characterization of the anti-hepatitis B virus activity and cross-resistance profile of 2',3'-dideoxy-3'-fluoroguanosine. Antimicrob Agents Chemother. 2006; 50(3):955-61. PMC: 1426422. DOI: 10.1128/AAC.50.3.955-961.2006. View

Sheldon J, Camino N, Rodes B, Bartholomeusz A, Kuiper M, Tacke F . Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther. 2005; 10(6):727-34. View

Chen C, Yang H, Su J, Jen C, You S, Lu S . Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006; 295(1):65-73. DOI: 10.1001/jama.295.1.65. View

McMahon M, Jilek B, Brennan T, Shen L, Zhou Y, Wind-Rotolo M . The HBV drug entecavir - effects on HIV-1 replication and resistance. N Engl J Med. 2007; 356(25):2614-21. PMC: 3069686. DOI: 10.1056/NEJMoa067710. View

Lai C, Shouval D, Lok A, Chang T, Cheinquer H, Goodman Z . Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2006; 354(10):1011-20. DOI: 10.1056/NEJMoa051287. View

10.

Soon D, Lowe S, Teng C, Yeo K, McGill J, Wise S . Safety and efficacy of alamifovir in patients with chronic hepatitis B virus infection. J Hepatol. 2004; 41(5):852-8. DOI: 10.1016/j.jhep.2004.07.028. View

11.

Choi J, Cho D, Roh K, Hwang J, Ahn S, Jang H . A novel class of phosphonate nucleosides. 9-[(1-phosphonomethoxycyclopropyl)methyl]guanine as a potent and selective anti-HBV agent. J Med Chem. 2004; 47(11):2864-9. DOI: 10.1021/jm0305265. View

12.

Kahn J, Lagakos S, Wulfsohn M, Cherng D, Miller M, Cherrington J . Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlled trial. JAMA. 1999; 282(24):2305-12. DOI: 10.1001/jama.282.24.2305. View

13.

Peters M, Andersen J, Lynch P, Liu T, Alston-Smith B, Brosgart C . Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. Hepatology. 2006; 44(5):1110-6. PMC: 4114764. DOI: 10.1002/hep.21388. View

14.

Lin C, Yeh L, Vitarella D, Hong Z, Erion M . Remofovir mesylate: a prodrug of PMEA with improved liver-targeting and safety in rats and monkeys. Antivir Chem Chemother. 2005; 15(6):307-17. DOI: 10.1177/095632020401500603. View

15.

Iloeje U, Yang H, Su J, Jen C, You S, Chen C . Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006; 130(3):678-86. DOI: 10.1053/j.gastro.2005.11.016. View

16.

Hadziyannis S, Tassopoulos N, Heathcote E, Chang T, Kitis G, Rizzetto M . Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology. 2006; 131(6):1743-51. DOI: 10.1053/j.gastro.2006.09.020. View

17.

van Bommel F, Wunsche T, Mauss S, Reinke P, Bergk A, Schurmann D . Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology. 2004; 40(6):1421-5. DOI: 10.1002/hep.20464. View

18.

Marcellin P, Lau G, Bonino F, Farci P, Hadziyannis S, Jin R . Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2004; 351(12):1206-17. DOI: 10.1056/NEJMoa040431. View

19.

Chang T, Gish R, de Man R, Gadano A, Sollano J, Chao Y . A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006; 354(10):1001-10. DOI: 10.1056/NEJMoa051285. View

20.

Marcellin P, Chang T, Lim S, Tong M, Sievert W, Shiffman M . Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med. 2003; 348(9):808-16. DOI: 10.1056/NEJMoa020681. View